QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Income Statement
USA - NASDAQ:QNRX - US74907L4095 - ADR
10.69 USD
-0.61 (-5.4%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 12.68M | 9.53M | 9.38M | 9.26M | 6.06M | |||
| Research and Development | 6.67M | 3.60M | 3.31M | 2.67M | 1.56M | |||
| Selling, General, and Administrative Expenses | 6.02M | 5.93M | 6.07M | 6.58M | 4.50M | |||
| Operating Income | -12.68M | -9.53M | -9.38M | -9.26M | -6.06M | |||
| Interest Income/Expense | 514.10K | 566.00K | 691.90K | -617.00K | -1.37M | |||
| Other Income/Expense | N/A | N/A | 0.00 | 77.20K | -14.03M | |||
| Non Recurring Items | N/A | N/A | 0.00 | 416.00K | N/A | |||
| Income Before Taxes | -12.17M | -8.96M | -8.69M | -9.38M | -21.46M | |||
| Income Tax | N/A | N/A | N/A | N/A | 0.00 | |||
| Net Income | -12.17M | -8.96M | -8.69M | -9.45M | -21.46M | |||
| EBITDA | -12.58M | -9.43M | -9.27M | -9.15M | -5.96M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -13.60 | -1.91 | -9.64 | 0.00 | -0.01 | |||
| Non GAAP EPS | -41.48 | -81.20 | -358.40 | -2.98K | N/A | |||
| Statistics | ||||||||
All data in USD